On June 30, 2025, David Mcclung, Chief Financial Officer of BioCardia Inc, purchased 4,819 shares of BioCardia Inc (BCDA, Financial). Following this transaction, the insider now owns a total of 47,950 shares in the company. The transaction details can be found in the SEC Filing.
BioCardia Inc is a clinical-stage regenerative medicine company focused on developing novel therapeutics to treat cardiovascular diseases. The company's product candidates include CardiAMP and CardiALLO cell therapies, which are designed to improve heart function and quality of life for patients with heart failure.
The insider's recent purchase is part of a broader trend within the company. Over the past year, David Mcclung has acquired a total of 17,942 shares, with no shares sold. In the same period, BioCardia Inc has seen 27 insider buys and only 1 insider sell.
On the day of the purchase, BioCardia Inc's shares were trading at $2.08, giving the company a market cap of $10.791 million. According to the GF Value, the stock is considered significantly overvalued with a price-to-GF-Value ratio of 52. The GF Value is an intrinsic value estimate that considers historical multiples, a GuruFocus adjustment factor, and future business performance estimates.
The GF Value is calculated using historical multiples such as the price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow. It also includes a GuruFocus adjustment factor based on the company's past returns and growth, as well as future estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
